{
    "nct_id": "NCT05621096",
    "official_title": "Feasibility of Low Dose Radiation as Bridging Therapy for Lisocabtagene Maraleucel in Relapsed B-Cell Non-Hodgkin Lymphoma",
    "inclusion_criteria": "1. Biopsy-proven relapsed or progressive diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, grade 3B follicular lymphoma, or DLBCL arising from indolent lymphoma meeting an FDA-approved (Food and Drug Administration-approved) indication for liso-cel infusion\n2. Presence of disease on imaging including at least one disease site safe for radiation as determined by treating radiation oncologist\n3. Willingness to participate in clinical trial and provide informed consent\n4. Adequate organ function as assessed by standard institution protocols and United States (US) prescribing information label for comorbidities, heart, and lung function to undergo FDA-approved CAR T-cell therapy as determined by institution\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n6. Age 19 years or older, there is no upper limit to the age\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "1. Subject is unsafe for radiation therapy as determined by investigator and/or radiation oncologist\n2. Diagnosis is primary central nervous system (CNS) lymphoma (secondary CNS lymphoma with additional systemic site is allowed)\n3. Requirement for concurrent high dose methotrexate\n4. Secondary active malignancy that has not been in remission for at least 2 years. This excludes non-melanoma skin cancer, definitively treated stage 1 solid tumor with low risk or recurrence, and curatively treated localized prostate cancer.\n5. Pregnant or nursing women\n6. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as determined by investigator\n7. Unwillingness to follow procedures required in the protocol\n8. Inadequate organ or hematologic conditions that prohibit the use of lymphodepleting chemotherapy\n9. Use of lymphoma-directed therapy within 14 days of T-cell pheresis",
    "miscellaneous_criteria": ""
}